CoChat

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1

Open access

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Abstract

An assay recapitulating the 3' processing activity of HIV-1 integrase (IN) was used to screen the Boehringer Ingelheim compound collection. Hit-to-lead and lead optimization beginning with compound 1 established the importance of the C3 and C4 substituent to antiviral potency against viruses with different aa124/aa125 variants of IN. The importance of the C7 position on the serum shifted potency was established. Introduction of a quinoline substituent at the C4 position provided a balance of potency and metabolic stability. Combination of these findings ultimately led to the discovery of compound 26 (BI 224436), the first NCINI to advance into a phase Ia clinical trial.

Overview

Integrity signals

Registry

Crossref · 10.1021/ml500002n

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 5

  1. Clavel F., 2004, N. Engl. J. Med., 350, 1023, 10.1056/nejmra025195 · doi:10.1056/nejmra025195 · Paper page
  2. Arribas J. R., 2013, Curr. Opin. HIV AIDS, 8, 341
  3. aFenwick, C.; Bethell, R.; Bonneau, P.; Duan, J.; Faucher, A.M.; Mason, S.; Poupart, M.A.; Simoneau, B.; Tsantrizos, Y.; Yoakim, C.Identification of BI-C, a novel HIV-1 non-catalytic site integrase inhibitor.18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 27 February–3 March, 2011 (abstract 523).
  4. bSimoneau, B.; Amad, M.; Bailey, M. D.; Bethell, R.; Bhardwaj, P. K.; Bilodeau, F.; Bonneau, P.; Bös, M.; Bousquet, Y.; Brochu, C.; Carson, R.; Chabot, C.; Cordingley, M.; Coulombe, R.; Duan, J.; Edwards, P.; Fader, L.; Faucher, A.M.; Fenwick, C.; Garneau, M.; Halmos, T.; Jakalian, A.; Kawai, S.; Landry, S.; Laplante, S.; Malenfant, E.; Mason, S.; Morin, S.; Parisien, M.; Pesant, M.; Poupart, M.A.; Tsantrizos, Y.; Wernic, D.; Yoakim, C.Identification of Novel Non-Catalytic Site Integrase Inhibitors (NCINIs) of LTR DNA 3′ Processing.24th International-Conference on Antiviral Research, Sofia, Bulgaria, May 8–11th, 2011, (Late Breaker abstract).
  5. Feng L., 2013, J. Biol. Chem., 288, 15813, 10.1074/jbc.m112.443390 · DOI · Paper page

Cited by

See all 199

Metadata

Authors
Fader, L. D., Malenfant, E., Parisien, M., Carson, R., Bilodeau, F., Landry, S., Pesant, M., Brochu, C., Morin, S., Chabot, C., Halmos, T., Bousquet, Y., Bailey, M. D., Kawai, S. H., Coulombe, R., LaPlante, S., Jakalian, A., Bhardwaj, P. K., Wernic, D., Schroeder, P., Amad, M., Edwards, P., Garneau, M., Duan, J., Cordingley, M., Bethell, R., Mason, S. W., Bös, M., Bonneau, P., Poupart, M.-A., Faucher, A.-M., Simoneau, B., Fenwick, C., Yoakim, C., & Tsantrizos, Y.
Affiliations
  • Boehringer Ingelheim (Canada) (CA)
  • Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval, Québec H7S 2G5, Canada
Corresponding author
Fader, Lee D.
Venue
ACS Medicinal Chemistry Letters
Published
2014-01-28
Volume
5
Issue
4
Pages
422-427
ISSN
1948-5875 (ISSN-L)
OpenAlex
W2000546717
Cited by
178
References
23
Citations by year
2026: 9 · 2025: 16 · 2024: 13 · 2023: 15 · 2022: 12 · 2021: 15 · 2020: 19 · 2019: 17 · 2018: 12 · 2017: 10 · 2016: 20 · 2015: 11 · 2014: 9
FWCI
11.95
Type
journal article
Language
en
Open access
Locations
  • ACS Medicinal Chemistry Letters (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
HIV-1 integrase, antiviral drug discovery, hit-to-lead optimization, metabolic stability, lead optimization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.